2.76
price down icon3.83%   -0.11
after-market After Hours: 2.77 0.01 +0.36%
loading
Immunitybio Inc stock is traded at $2.76, with a volume of 6.72M. It is down -3.83% in the last 24 hours and up +9.09% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.87
Open:
$2.81
24h Volume:
6.72M
Relative Volume:
0.75
Market Cap:
$2.95B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.8454
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-11.82%
1M Performance:
+9.09%
6M Performance:
+3.37%
1Y Performance:
-61.98%
1-Day Range:
Value
$2.64
$2.87
1-Week Range:
Value
$2.64
$3.12
52-Week Range:
Value
$1.83
$7.63

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
671
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.76 2.95B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.54 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
511.92 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
540.76 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.51 28.51B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Jun 17, 2025

ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News

Jun 17, 2025
pulisher
Jun 12, 2025

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum

Jun 12, 2025
pulisher
Jun 12, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN

Jun 12, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 07, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView

Jun 06, 2025
pulisher
Jun 05, 2025

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwright | IBRX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cancer Treatment Granted Lymphopenia Indication - Vax-Before-Travel

Jun 04, 2025
pulisher
Jun 03, 2025

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com

Jun 03, 2025
pulisher
Jun 03, 2025

ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

ImmunityBio (IBRX) Gains FDA Nod for Cancer BioShield Platform - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio (IBRX) Gains FDA Approval for Expanded Access to Can - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Placera.se

Jun 02, 2025
pulisher
Jun 02, 2025

Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA - Business Wire

Jun 02, 2025
pulisher
May 30, 2025

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com

May 30, 2025
pulisher
May 30, 2025

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail

May 30, 2025
pulisher
May 29, 2025

ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView

May 29, 2025
pulisher
May 29, 2025

ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView

May 29, 2025
pulisher
May 29, 2025

While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey

May 29, 2025
pulisher
May 28, 2025

ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX S - GuruFocus

May 28, 2025
pulisher
May 28, 2025

ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace

May 27, 2025
pulisher
May 27, 2025

ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News

May 23, 2025
pulisher
May 22, 2025

Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World

May 22, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
SOON-SHIONG PATRICK
See remarks
Feb 22 '25
Option Exercise
0.00
114,329
0
29,588,261
Sachs David C.
Chief Financial Officer
Feb 22 '25
Option Exercise
0.00
40,650
0
241,480
Adcock Richard
CEO & President
Feb 22 '25
Option Exercise
0.00
152,439
0
412,585
Simon Barry J.
Director
Feb 22 '25
Option Exercise
0.00
15,243
0
3,249,024
Simon Barry J.
Director
Jan 22 '25
Option Exercise
2.00
110,020
219,864
3,233,781
Adcock Richard
CEO & President
Dec 31 '24
Option Exercise
0.00
34,483
0
277,621
Sachs David C.
Chief Financial Officer
Dec 31 '24
Option Exercise
0.00
30,397
0
216,235
LAUER REGAN J
Chief Accounting Officer
Dec 15 '24
Option Exercise
0.00
21,031
0
115,365
$20.68
price down icon 2.27%
$35.40
price up icon 1.55%
$20.39
price down icon 0.83%
$105.42
price up icon 2.67%
$103.01
price down icon 3.30%
biotechnology ONC
$257.51
price up icon 4.22%
Cap:     |  Volume (24h):